162 results
6-K
EX-99
BLRX
Bioline Rx Ltd
23 Dec 14
Current report (foreign)
12:00am
of the largest OTC healthcare companies in Europe, for the rights to BioLineRx’s BL-5010, a novel product for the non-surgical removal of benign skin lesions … are very pleased to partner with Omega Pharma, a top consumer healthcare company and a leading provider of over-the-counter medicines and healthcare
6-K
EX-99
BLRX
Bioline Rx Ltd
13 Oct 21
BioLineRx Announces Positive Results from
8:37am
in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.
“The compelling cost savings identified by this rigorously designed … healthcare resource utilization (HRU) observed during the Phase 3 GENESIS trial, which randomized 122 patients into two arms: Motixafortide plus G
6-K
EX-99
BLRX
Bioline Rx Ltd
15 Sep 22
Current report (foreign)
8:39am
to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.
Per the terms of the agreement, the first tranche … the support of Kreos Capital, a well-known and highly regarded healthcare investor, as we prepare to transition to a commercial stage company next year
6-K
EX-99
BLRX
Bioline Rx Ltd
24 Feb 14
BioLineRx Appoints Dr. Sandra Panem to
12:00am
, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Dr. Panem has had an extensive and impressive career in the healthcare … in healthcare strategy, technology assessment and capital markets experience, and we expect that she will add great value to our Company as we
6-K
EX-99
BLRX
Bioline Rx Ltd
3 Mar 22
BioLineRx Announces Additional Positive Results from
7:10am
) values for healthcare payers.
“The results of this pharmacoeconomic study have now demonstrated significant net cost savings of using Motixafortide … relevant deteriorations in their quality of life during ASCT, and healthcare resource use throughout the ASCT phases is particularly intense. Therefore, new
6-K
EX-99
zjzav vg27u4rue
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
EX-99
hbi3jhn1f52bvn
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.3
3v5ad3l1n9i1nagl1
3 Mar 14
Current report (foreign)
12:00am
6-K
EX-99
d7xjezjsey
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
424B3
mhdac9x07k9zo1
2 Aug 12
Prospectus supplement
12:00am
6-K
EX-99.3
00q 391ut
5 Mar 15
Current report (foreign)
12:00am
6-K
EX-99
50503 m9w
10 Nov 22
Current report (foreign)
7:08am
6-K
2klmc3
16 Feb 12
Current Report, Foreign Issuer
12:00am
F-3/A
lg9sp7hlik 27z
23 Jul 12
Shelf registration (foreign) (amended)
12:00am
6-K
p2idktqinj83g
27 Feb 12
BioLineRx Ltd. Announces Closing of $15 millionPrivate Placement to Institutional Investors
12:00am
POS AM
n8ii2ci hp4kt4xyum4t
25 Jul 12
Prospectus update (post-effective amendment)
12:00am
6-K
x6g5ysdcgw8rtwkd
30 Apr 13
Current report (foreign)
12:00am
6-K
4ep9efftp5oiq 10z3n
13 Feb 13
BioLineRx Announces Closing of $8 Million Offering of American
12:00am
20-F/A
xookn dabt
26 Mar 24
Annual report (foreign) (amended)
4:57pm